Benzinga | Dec 22, 2021 06:45AM EST

Raymond James Maintains Outperform on Abbott Laboratories, Raises Price Target to $150

Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $134 to $150.